HORSHAM, PA (June 24, 2025) – Myonex, a global leader in integrating clinical trial and commercial pharmaceutical services to reduce time, costs, and complexity, is proud to announce that The Leukemia & Lymphoma Society (LLS) has selected Myonex as its preferred partner to support patients participating in the LLS-sponsored Beat AML® Master Clinical Trial through its CTRx™ solution. This choice will help ensure uninterrupted access to commercial medications and comprehensive patient financial assistance from LLS.
Recognizing the critical need to support patients in its trial, LLS turned to Myonex to manage its medication support program with speed and precision, ensuring continuity of care for patients who previously worked with another partner.
“We look forward to partnering with LLS, a remarkable nonprofit committed to advancing blood cancer research and supporting patients and their families,” said James Lovett, CEO of Myonex. “Supporting LLS aligns perfectly with Myonex’s mission to ensure patients receive life-changing medicines through agile, innovative services and solutions. We are proud to support LLS in removing barriers and improving outcomes for blood cancer patients through impactful clinical research.”
Myonex is swiftly mobilizing its CTRx solution for the LLS patient access and assistance program, ensuring a seamless experience for both patients and investigators. Above all, patient care will continue uninterrupted, reflecting Myonex’s agility and commitment to operational excellence in high-stakes clinical settings. CTRx continues to be the industry’s only pharmacist-led solution that uniquely integrates prescription card services, global pharmacy dispensing, and centralized local drug supply.
“We are excited to partner with Myonex,” said Ashley Yocum, Ph.D., Beat AML master protocol lead, LLS. “Their team brings exceptional project management and a deep understanding of the patient journey. With Myonex, we are confident in our ability to effectively administer financial assistance and medication access programs across our Beat AML subtrials.”
This work with LLS underscores Myonex’s ability to respond to critical needs, deliver robust patient services, and foster long-standing, mission-aligned partnerships. Both organizations are looking ahead to a productive and impactful relationship that supports innovation in blood cancer research and care delivery.
About Myonex
Myonex is an industry leader in global clinical trial supply and pharmaceutical commercial services. Our suite of integrable services and solutions helps pharmaceutical, biotech, and CRO partners advance medicine by reducing time, costs, and complexity. With locations in the US, Germany, UK, and France, our comprehensive, client-focused approach, coupled with expert project management, ensures seamless execution across regions, optimizes supply chain efficiency, and adapts to evolving trial or project needs while delivering quality, flexibility, and global scale. www.myonex.com.